Annual EBITDA
-$5.05 M
-$2.85 M-129.41%
30 April 2024
Summary:
Champions Oncology annual earnings before interest, taxes, depreciation & amortization is currently -$5.05 million, with the most recent change of -$2.85 million (-129.41%) on 30 April 2024. During the last 3 years, it has fallen by -$6.60 million (-426.06%). CSBR annual EBITDA is now -326.23% below its all-time high of $2.23 million, reached on 30 April 2022.CSBR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$1.78 M
+$1.16 M+186.31%
31 July 2024
Summary:
Champions Oncology quarterly earnings before interest, taxes, depreciation & amortization is currently $1.78 million, with the most recent change of +$1.16 million (+186.31%) on 31 July 2024. Over the past year, it has increased by +$3.25 million (+220.87%). CSBR quarterly EBITDA is now at all-time high.CSBR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$1.17 M
+$3.88 M+76.89%
31 July 2024
Summary:
Champions Oncology TTM earnings before interest, taxes, depreciation & amortization is currently -$1.17 million, with the most recent change of +$3.88 million (+76.89%) on 31 July 2024. Over the past year, it has increased by +$5.42 million (+82.28%). CSBR TTM EBITDA is now -150.00% below its all-time high of $2.34 million, reached on 31 July 2022.CSBR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CSBR EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -129.4% | +220.9% | +82.3% |
| 3 y3 years | -426.1% | +191.9% | -169.3% |
| 5 y5 years | -676.9% | +279.1% | -942.9% |
CSBR EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -326.2% | at low | at high | +184.4% | -150.0% | +82.8% |
| 5 y | 5 years | -326.2% | at low | at high | +184.4% | -150.0% | +82.8% |
| alltime | all time | -326.2% | +61.2% | at high | +148.4% | -150.0% | +91.0% |
Champions Oncology EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2024 | - | $1.78 M(+186.3%) | -$1.17 M(-76.9%) |
| Apr 2024 | -$5.05 M(+129.4%) | $621.00 K(-129.6%) | -$5.05 M(-25.7%) |
| Jan 2024 | - | -$2.10 M(+42.5%) | -$6.80 M(+3.2%) |
| Oct 2023 | - | -$1.47 M(-30.2%) | -$6.59 M(+44.8%) |
| July 2023 | - | -$2.11 M(+86.3%) | -$4.55 M(+106.7%) |
| Apr 2023 | -$2.20 M(-198.6%) | -$1.13 M(-39.9%) | -$2.20 M(+170.3%) |
| Jan 2023 | - | -$1.88 M(-432.1%) | -$815.00 K(-135.5%) |
| Oct 2022 | - | $567.00 K(+132.4%) | $2.29 M(-1.8%) |
| July 2022 | - | $244.00 K(-5.1%) | $2.34 M(+4.6%) |
| Apr 2022 | $2.23 M(+44.1%) | $257.00 K(-79.0%) | $2.23 M(+36.9%) |
| Jan 2022 | - | $1.23 M(+101.3%) | $1.63 M(-3.1%) |
| Oct 2021 | - | $609.00 K(+328.9%) | $1.69 M(+21.2%) |
| July 2021 | - | $142.00 K(-141.2%) | $1.39 M(-10.2%) |
| Apr 2021 | $1.55 M(-303.7%) | -$345.00 K(-127.0%) | $1.55 M(+248.6%) |
| Jan 2021 | - | $1.28 M(+307.3%) | $444.00 K(-342.6%) |
| Oct 2020 | - | $314.00 K(+4.7%) | -$183.00 K(+553.6%) |
| July 2020 | - | $300.00 K(-120.7%) | -$28.00 K(-96.3%) |
| Apr 2020 | -$761.00 K(-186.9%) | -$1.45 M(-322.2%) | -$760.00 K(-201.9%) |
| Jan 2020 | - | $652.00 K(+39.0%) | $746.00 K(-766.1%) |
| Oct 2019 | - | $469.00 K(-208.6%) | -$112.00 K(-27.7%) |
| July 2019 | - | -$432.00 K(-857.9%) | -$155.00 K(-117.7%) |
| Apr 2019 | $876.00 K(-188.1%) | $57.00 K(-127.7%) | $876.00 K(+167.9%) |
| Jan 2019 | - | -$206.00 K(-148.4%) | $327.00 K(-44.3%) |
| Oct 2018 | - | $426.00 K(-28.9%) | $587.00 K(+224.3%) |
| July 2018 | - | $599.00 K(-221.7%) | $181.00 K(-118.2%) |
| Apr 2018 | -$994.00 K(-85.0%) | -$492.00 K(-1011.1%) | -$995.00 K(-65.1%) |
| Jan 2018 | - | $54.00 K(+170.0%) | -$2.85 M(-33.2%) |
| Oct 2017 | - | $20.00 K(-103.5%) | -$4.27 M(-9.9%) |
| July 2017 | - | -$577.00 K(-75.4%) | -$4.74 M(-28.6%) |
| Apr 2017 | -$6.64 M(-34.6%) | -$2.35 M(+72.5%) | -$6.64 M(-2.3%) |
| Jan 2017 | - | -$1.36 M(+201.8%) | -$6.80 M(-12.5%) |
| Oct 2016 | - | -$451.00 K(-81.8%) | -$7.77 M(-20.5%) |
| July 2016 | - | -$2.48 M(-1.2%) | -$9.77 M(-3.8%) |
| Apr 2016 | -$10.16 M(-22.0%) | -$2.51 M(+7.4%) | -$10.16 M(+1.5%) |
| Jan 2016 | - | -$2.33 M(-4.8%) | -$10.01 M(-9.3%) |
| Oct 2015 | - | -$2.45 M(-14.2%) | -$11.03 M(-9.5%) |
| July 2015 | - | -$2.86 M(+21.4%) | -$12.19 M(-6.3%) |
| Apr 2015 | -$13.02 M(+115.4%) | -$2.36 M(-29.9%) | -$13.00 M(+0.3%) |
| Jan 2015 | - | -$3.36 M(-6.9%) | -$12.97 M(+18.3%) |
| Oct 2014 | - | -$3.61 M(-1.7%) | -$10.96 M(+21.8%) |
| July 2014 | - | -$3.67 M(+58.1%) | -$9.00 M(+49.0%) |
| Apr 2014 | -$6.05 M(+0.5%) | -$2.32 M(+71.8%) | -$6.04 M(+6.8%) |
| Jan 2014 | - | -$1.35 M(-18.0%) | -$5.65 M(+13.7%) |
| Oct 2013 | - | -$1.65 M(+130.3%) | -$4.97 M(-4.2%) |
| July 2013 | - | -$716.00 K(-63.0%) | -$5.19 M(-13.8%) |
| Apr 2013 | -$6.02 M(-32.8%) | -$1.94 M(+189.0%) | -$6.02 M(-9.4%) |
| Jan 2013 | - | -$670.00 K(-64.1%) | -$6.64 M(-14.1%) |
| Oct 2012 | - | -$1.87 M(+20.8%) | -$7.73 M(-7.0%) |
| July 2012 | - | -$1.54 M(-39.7%) | -$8.31 M(-7.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Apr 2012 | -$8.96 M(+72.5%) | -$2.56 M(+45.8%) | -$8.95 M(-2.9%) |
| Jan 2012 | - | -$1.76 M(-28.3%) | -$9.22 M(+11.9%) |
| Oct 2011 | - | -$2.45 M(+12.1%) | -$8.24 M(+21.3%) |
| July 2011 | - | -$2.19 M(-22.7%) | -$6.79 M(+30.6%) |
| Apr 2011 | -$5.19 M(+79.3%) | -$2.83 M(+264.3%) | -$5.20 M(+78.2%) |
| Jan 2011 | - | -$776.00 K(-22.8%) | -$2.92 M(0.0%) |
| Oct 2010 | - | -$1.00 M(+69.5%) | -$2.92 M(+17.2%) |
| July 2010 | - | -$593.00 K(+9.0%) | -$2.49 M(-14.1%) |
| Apr 2010 | -$2.90 M(+41.8%) | -$544.00 K(-29.9%) | -$2.90 M(-16.7%) |
| Jan 2010 | - | -$776.00 K(+34.7%) | -$3.48 M(+5.8%) |
| Oct 2009 | - | -$576.00 K(-42.4%) | -$3.28 M(+10.8%) |
| July 2009 | - | -$1.00 M(-11.0%) | -$2.96 M(+40.1%) |
| Apr 2009 | -$2.04 M(+364.1%) | -$1.12 M(+92.5%) | -$2.12 M(+12.0%) |
| Jan 2009 | - | -$584.00 K(+127.5%) | -$1.89 M(+188.2%) |
| Oct 2008 | - | -$256.70 K(+68.9%) | -$656.10 K(+27.9%) |
| July 2008 | - | -$152.00 K(-83.1%) | -$513.10 K(+55.0%) |
| Apr 2008 | -$440.00 K(+176.7%) | -$898.00 K(-238.0%) | -$331.10 K(-170.3%) |
| Jan 2008 | - | $650.60 K(-672.2%) | $470.90 K(-317.1%) |
| Oct 2007 | - | -$113.70 K(-479.0%) | -$216.90 K(+76.6%) |
| July 2007 | - | $30.00 K(-131.3%) | -$122.80 K(-27.8%) |
| Apr 2007 | -$159.00 K(+10.3%) | -$96.00 K(+158.1%) | -$170.10 K(+138.2%) |
| Jan 2007 | - | -$37.20 K(+89.8%) | -$71.40 K(-361.5%) |
| Oct 2006 | - | -$19.60 K(+13.3%) | $27.30 K(+780.6%) |
| July 2006 | - | -$17.30 K(-740.7%) | $3100.00(-106.3%) |
| Apr 2006 | -$144.10 K(+36.6%) | $2700.00(-95.6%) | -$49.60 K(-229.8%) |
| Jan 2006 | - | $61.50 K(-240.4%) | $38.20 K(0.0%) |
| Oct 2005 | - | -$43.80 K(-37.4%) | $38.20 K(+496.9%) |
| July 2005 | - | -$70.00 K(-177.3%) | $6400.00(-63.6%) |
| Apr 2005 | -$105.50 K(+77.9%) | $90.50 K(+47.2%) | $17.60 K(+19.7%) |
| Jan 2005 | - | $61.50 K(-181.3%) | $14.70 K(-116.6%) |
| Oct 2004 | - | -$75.60 K(+28.6%) | -$88.70 K(+164.0%) |
| July 2004 | - | -$58.80 K(-167.1%) | -$33.60 K(+236.0%) |
| Apr 2004 | -$59.30 K(-39.2%) | $87.60 K(-309.1%) | -$10.00 K(-93.3%) |
| Jan 2004 | - | -$41.90 K(+104.4%) | -$149.80 K(+7.8%) |
| Oct 2003 | - | -$20.50 K(-41.8%) | -$138.90 K(+100.1%) |
| July 2003 | - | -$35.20 K(-32.6%) | -$69.40 K(-28.9%) |
| Apr 2003 | -$97.60 K(-1.3%) | -$52.20 K(+68.4%) | -$97.60 K(-13.3%) |
| Jan 2003 | - | -$31.00 K(-163.3%) | -$112.60 K(+5.6%) |
| Oct 2002 | - | $49.00 K(-177.3%) | -$106.60 K(-24.1%) |
| July 2002 | - | -$63.40 K(-5.7%) | -$140.50 K(+42.1%) |
| Apr 2002 | -$98.90 K(-76.0%) | -$67.20 K(+168.8%) | -$98.90 K(+17.2%) |
| Jan 2002 | - | -$25.00 K(-265.6%) | -$84.40 K(-74.0%) |
| Oct 2001 | - | $15.10 K(-169.3%) | -$324.90 K(-33.4%) |
| July 2001 | - | -$21.80 K(-58.6%) | -$487.60 K(+18.2%) |
| Apr 2001 | -$412.60 K(-717.7%) | -$52.70 K(-80.2%) | -$412.50 K(-7.3%) |
| Jan 2001 | - | -$265.50 K(+79.9%) | -$444.80 K(+148.1%) |
| Oct 2000 | - | -$147.60 K(-376.9%) | -$179.30 K(+465.6%) |
| July 2000 | - | $53.30 K(-162.7%) | -$31.70 K(-62.7%) |
| Apr 2000 | $66.80 K | -$85.00 K(<-9900.0%) | -$85.00 K(<-9900.0%) |
| Jan 2000 | - | $0.00 | $0.00 |
FAQ
- What is Champions Oncology annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Champions Oncology?
- What is Champions Oncology annual EBITDA year-on-year change?
- What is Champions Oncology quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Champions Oncology?
- What is Champions Oncology quarterly EBITDA year-on-year change?
- What is Champions Oncology TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Champions Oncology?
- What is Champions Oncology TTM EBITDA year-on-year change?
What is Champions Oncology annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CSBR is -$5.05 M
What is the all time high annual EBITDA for Champions Oncology?
Champions Oncology all-time high annual earnings before interest, taxes, depreciation & amortization is $2.23 M
What is Champions Oncology annual EBITDA year-on-year change?
Over the past year, CSBR annual earnings before interest, taxes, depreciation & amortization has changed by -$2.85 M (-129.41%)
What is Champions Oncology quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CSBR is $1.78 M
What is the all time high quarterly EBITDA for Champions Oncology?
Champions Oncology all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.78 M
What is Champions Oncology quarterly EBITDA year-on-year change?
Over the past year, CSBR quarterly earnings before interest, taxes, depreciation & amortization has changed by +$3.25 M (+220.87%)
What is Champions Oncology TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CSBR is -$1.17 M
What is the all time high TTM EBITDA for Champions Oncology?
Champions Oncology all-time high TTM earnings before interest, taxes, depreciation & amortization is $2.34 M
What is Champions Oncology TTM EBITDA year-on-year change?
Over the past year, CSBR TTM earnings before interest, taxes, depreciation & amortization has changed by +$5.42 M (+82.28%)